Showing results (1921-1930 of 3,641) with videos related to

Sort By:
Pageof 365
Breast (Edinburgh, Scotland)|April 1, 2014
Evaluation of eligibility and recruitment in breast cancer clinical trialsJulie Lemieux, Geneviève Forget, Olyvia Brochu, et al.
Breast (Edinburgh, Scotland)|April 15, 2014
Portrait, treatment choices and management of breast cancer in nonagenarians: an ongoing challengeBenoite Méry, Avi Assouline, Romain Rivoirard, et al.
Breast (Edinburgh, Scotland)|April 8, 2014
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtypingSotiris Lakis, Vassiliki Kotoula, Anastasia G Eleftheraki, et al.
Breast (Edinburgh, Scotland)|February 13, 2014
Surgical excision of pure flat epithelial atypia identified on core needle breast biopsyVanessa L Prowler, Jennifer E Joh, Geza Acs, et al.
Breast (Edinburgh, Scotland)|February 18, 2014
Evaluation of expert criteria for preoperative magnetic resonance imaging of newly diagnosed breast cancerCarolyn E Behrendt, Lusine Tumyan, Laura Gonser, et al.
Breast (Edinburgh, Scotland)|February 26, 2017
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilarsChristian Jackisch, Philip Lammers, Ira Jacobs
Breast (Edinburgh, Scotland)|March 9, 2017
Trial sponsorship and self-reported conflicts of interest in breast cancer radiation therapy: An analysis of prospective clinical trialsElton T T Leite, Fabio Y Moraes, Gustavo N Marta, et al.
Breast (Edinburgh, Scotland)|March 11, 2017
Evaluation of percutaneous vacuum assisted intact specimen breast biopsy device for ultrasound visualized breast lesions: Upstage rates and long term follow-up for high risk lesions and DCISCathy L Graham
Breast (Edinburgh, Scotland)|January 28, 2017
Seroma indicates increased risk of lymphedema following breast cancer treatment: A retrospective cohort studyNavid Mohamadpour Toyserkani, Mads Gustaf Jørgensen, Karen Haugaard, et al.
Breast (Edinburgh, Scotland)|January 6, 2017
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanesShigeto Maeda, Michiyo Saimura, Shigeki Minami, et al.
Pageof 365